North Jersey Section
American Chemical Society

Sep 13, 2016 – MSDG Symposium & Vendor Show

NJ-ACS Mass Spec Discussion Group
The NJ Mass Spectrometry Discussion Group is pleased again this year to announce our “Annual NJMSDG Vendor Night, Meeting and Poster Session”.

NJ MSDG is the second largest mass spectrometry professional association in the nation behind ASMS, with over 1,100 members in the tristate area. [ homepage ]

We had a fantastic turn out for our last year’s vendor show (~250 attendees) with guest lectures given by luminaries such as Professor Tom Baillie (former VP of Drug Metabolism and Pharmacokinetics at Merck and currently Dean Emeritus at University of Washington School of Pharmacy), and Professor Richard Capprioli (Stanford Moore Chair in Biochemistry and Director of the Mass Spectrometry Research Center at Vanderbilt University School of Medicine).

This year, we are pleased to announce that Professor David Muddiman, from North Carolina State University, will be one of our guest lecturer. The other presentation will be given by Dr. Wilson Shou of Bristol-Myers Squibb Co.

Don’t miss this incredible network, learning and cross-fertilization opportunity. Save the date!

      September 13, 2016

Holiday Inn Somerset-Bridgewater

    195 Davison Avenue, Somerset, NJ 08873

More than 200 attendees expected

Please  register here.  Registration is free.


2:30 – 8:00 PM         Vendor Show

2:30 – 3:00 PM         Vendor Set Up – Hotel Ballroom

3:00 – 4:00 PM         Registration – Hotel Ballroom

4:15 – 4:45 PM         Cocktail Break / vendor interaction

4:45 – 5:45 PM        Presentation by Professor David Muddiman (North Carolina State University)  Title: Working Around the Cluck:  A Systems Biology Approach to Understanding the Origin and Biology of Ovarian Cancer.

7:00 – 8:00 PM        Presentation by Dr. Wilson Shou (from BMS) , Title:  Quest for a Mass Spectrometry-Based Plate Reader:  Coupling Laser Diode Thermal Desorption (LDTD) with Nanoliter Sample Transfer for Label-free High Throughput Screening

Abstract: Dr. David Muddiman

Mass spectrometry offers the most robust platform to discover and characterize new diagnostic, prognostic, and therapeutic biomarkers for ovarian cancer across all molecular classes. Moreover, a systems biology approach will allow the underlying biology and origin of ovarian cancer to be understood. This presentation will discuss the challenges specific to the study of epithelial ovarian cancer (EOC) in humans and how these challenges have directed our thinking in terms of the development of model organisms and mass spectrometry-based bioanalytical strategies. First, to augment the human model, we developed the domestic hen model of spontaneous EOC, which allowed us to longitudinally sample the rapid onset and progression of the disease in a controlled environment. Second, we developed bioanalytical tools to characterize structurally challenging analytes that are critical to a systems-level analysis. To increase the electrospray response of N-linked glycans, we synthesized novel hydrophobic tagging reagents which have the added benefit of being able to incorporate a stable-isotope label for relative quantification experiments (INLIGHTTM). Furthermore, we developed a novel ionization technique for tissue imaging of lipids and metabolites. This unique model organism has and continues to provide new insights into the biology of ovarian cancer; combined with other –OMICS data obtained through these novel bioanalytical approaches, we will understand the origin of ovarian cancer and ultimately translate that knowledge to humans.


David C. Muddiman is the Jacob and Betty Belin Distinguished Professor of Chemistry and Founder and Director of the W.M. Keck FTMS Laboratory for Human Health Research at North Carolina State University in Raleigh, NC. Prior to moving his research group to North Carolina State University, David was a Professor of Biochemistry and Molecular Biology and Founder and Director of the Mayo Proteomics Research Center at the Mayo Clinic College of Medicine in Rochester, MN. Prior to his appointment at the Mayo Clinic, David was an Associate Professor of Chemistry at Virginia Commonwealth University where he began his academic career as an assistant professor in 1997 with an adjunct appointment in the Department of Biochemistry and Molecular Biophysics where he was also a member of the Massey Cancer Center. David was born in Long Beach, CA in 1967 but spent most of his formative years in a small town in Pennsylvania. David received his B.S. in chemistry from Gannon University (Erie, PA) in 1990 and his Ph.D. in Analytical Chemistry from the University of Pittsburgh in 1995 under the auspices of David M. Hercules. He then was a Department of Energy Postdoctoral Fellow at Pacific Northwest National Laboratory in the Environmental Molecular Sciences Laboratory working with Richard D. Smith from 1995-1997. Dr. Muddiman is Editor of Analytical and Biological Chemistry and Associate Editor of the Encyclopedia of Analytical Chemistry as well as on the Editorial Advisory Board of Mass Spectrometry Reviews, Molecular and Cellular Proteomics, Rapid Communications in Mass Spectrometry, and the Journal of Chromatography B. He also serves on the advisory board of the NIH Funded Complex Carbohydrate Research Center, University of Georgia and the Yale/NIDA Neuroproteomics Center, Yale University. Dr. Muddiman served as a member of the ASMS Board of Directors and Treasurer of US-HUPO; he is currently the President of US HUPO. His group has presented over 500 invited lectures and presentations at national and international meetings including 20 plenary/keynote lectures. His group has published over 225 peer-reviewed papers and has received four US patents. He is the recipient of the 2015 ACS Award in Chemical Instrumentation, 2010 Biemann Medal, American Society for Mass Spectrometry, 2009 NCSU Alumni Outstanding Research Award, the 2004 ACS Arthur F. Findeis Award, the 1999 American Society for Mass Spectrometry Research Award, and the 1990-91 Safford Award, University of Pittsburgh, for Excellence in Teaching. Dr. Muddiman’s research directed at the development of innovative technologies, systems biology, and model organisms is funded by the National Institutes of Health, the National Science Foundation, the Department of Energy, and The United States Department of Agriculture.

Abstract:Dr. Wilson Shou

Improvements in mass spectrometry (MS)-based analytical throughput have been achieved using laser desorption ionization (LDI) techniques and this has led to increased utility for this technology amongst research groups supporting early drug discovery efforts.  In particular, lead discovery teams that perform high-throughput screening (HTS) assays that are intended to identify active compounds against therapeutic targets of interest have begun to adopt this label-free methodology as an orthogonal screening approach to well-established fluoresence-based assays. Furthermore, optimization of the “hits” identified through HTS requires additional in vitro studies to assess absorption, distribution, metabolism, and elimination (ADME) properties by lead profiling groups who prefer to use native, clinically-relevant substrates.  Since HTS and HT-ADME groups can generate thousands of samples on a daily basis, it is necessary to have high-throughput analytical platforms capable of processing these demands.  The move towards label-free screening in drug discovery has increased the demand for mass spectrometry-based analysis, and because of this, it is important to explore new technologies aimed at improving MS-based readout speeds in order to continue to support the increasing sample volume demands of these groups.

Assays that utilize mass spectrometry for analysis are both sensitive and selective and offer the ability to provide label-free detection of physiologically relevant substrates and products.  MS-based methodologies, however, have traditionally relied upon liquid chromatography (LC) or on-line solid phase extraction (SPE) as front-end sample delivery mechanisms. Because of this, they typically have slow cycle times that aren’t amenable to high throughput screening efforts. Using newer approaches that employ laser desorption techniques to directly introduce the contents of wells into the mass spectrometer, it is possible to achieve throughputs that approach those of plate-reader assays and meet the demands of early discovery screening applications. Here we investigated the approach of coupling nanoliter sample deposition with Laser Diode Thermal Desorption (LDTD) – tandem mass spectrometry (MS/MS) and evaluated its utility in providing an ultra high-throughput, label-free detection method for various applications in HTS and HT-ADME groups.